Publications by authors named "P Wurth"
Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network.
Patrick-Pascal Strunz Matthias Englbrecht Linus Maximilian Risser Torsten Witte Matthias Froehlich Patrick Wurth
Rheumatol Int
October 2024
Article Synopsis
- Janus kinase inhibitors (JAKi) have recently been approved alongside tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) as treatment options for axial spondyloarthritis (axSpA), yet their real-world drug survival is under-studied.
- A retrospective analysis of 1,222 axSpA patients, focusing on treatment initiation timing from January 2015 to October 2023, reveals median drug survival rates of 31 months for TNFi, 25 months for IL-17i, and 18 months for JAKi.
- Higher discontinuation rates were seen for JAKi and IL-17i compared to TNFi, with
Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database.
Patrick-Pascal Strunz Matthias Englbrecht Linus Maximilian Risser Torsten Witte Matthias Froehlich Patrick Wurth
Front Immunol
June 2024
Article Synopsis
- Treatment options for psoriatic arthritis have expanded to include various biologic DMARDs and Janus kinase inhibitors, but real-world data on their persistence in patients is limited.
- A study analyzed 1352 prescriptions and found that the 5-year survival rates were highest for IL-17 inhibitors (67.8%) and lowest for IL-12/23 inhibitors (46.0%), with JAKi showing a higher likelihood of discontinuation.
- The findings suggest that patients in Germany may stick with TNFi and IL-17i longer than IL-12/23i or JAKi, potentially influenced by disease severity and other health conditions like osteoarthritis.
Article Synopsis
- The study explored the differentiation between radiographic (r-axSpA) and non-radiographic (nr-axSpA) axial spondyloarthritis in a real-world clinical setting, analyzing data from 371 patients in Germany.
- Findings showed that nearly half of the patients were classified as having definite r-axSpA, with those in this category receiving more aggressive treatment options like disease-modifying antirheumatic drugs (DMARDs) compared to nr-axSpA patients.
- The availability of radiographic imaging was limited, with only about 58% of patients having the necessary imaging documentation, and follow-up imaging was rare; however, it confirmed r-axSpA in approximately 40
Article Synopsis
- * Patients with axSpA displayed greater impairments in selective attention compared to matched healthy individuals, while the PsA group showed better episodic short-term memory performance.
- * Further research is needed to explore factors influencing cognitive changes; the current study suggests that impairments in selective attention could affect information processing in these patients.
This longitudinal analysis compares the prevalence of depressive symptoms in patients with psoriatic arthritis in the context of the COVID-19 pandemic. Data from a national patient register in Germany were analyzed regarding the Patient Health Questionnaire 2 (PHQ-2) to identify cases suspicious for depression at two time points, i.e.
View Article and Find Full Text PDF